Quotes 5-day view Delayed Nasdaq
11/24/2020
11/25/2020
11/27/2020
11/30/2020
12/01/2020
Date
223.41(c)
225.46(c)
232.54(c)
237.85(c)
234.36(c)
Last
363 580
283 843
202 849
618 586
411 129
Volume
-0.71% +0.92% +3.14% +2.28% -1.47% Change
Sales 2020
12,0 M - -
Net income 2020
-367 M - -
Net cash position 2020
986 M - -
P/E ratio 2020
-29,0x
Yield 2020
-
Sales 2021
14,7 M - -
Net income 2021
-414 M - -
Net cash position 2021
870 M - -
P/E ratio 2021
-28,2x
Yield 2021
-
Capitalization
11 959 M 11 959 M -
EV / Sales 2020
915x
EV / Sales 2021
755x
Nbr of Employees
-
Free-Float
91,3%
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS...
Notations Surperformance© of Mirati Therapeutics, Inc.
Trading Rating : Investor Rating :
All news about MIRATI THERAPEUTICS, INC.
News in other languages on MIRATI THERAPEUTICS, INC.
- No features available -
Chart MIRATI THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MIRATI THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
14
Average target price
230,62 $
Last Close Price
237,85 $
Spread / Highest target
11,4%
Spread / Average Target
-3,04%
Spread / Lowest Target
-26,0%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
